There are a number of patients in the UAE who face cost as a barrier to completing or adhering to their treatment.
Low-income patients suffering from multiple sclerosis, eczema, and some cases of severe asthma are set to benefit from a new initiative that will ensure their permanent access to their treatments.
The Ministry of Health and Prevention (MoHAP) recently signed a memorandum of understanding (MoU) with Sanofi Aventis Group and Axios Health Education Services, paving the way for the launch of a programme called ‘Ea’nah’ (Support).
Mohap’s ‘Ea’nah’ will provide appropriate medicines to financially troubled patients with no or limited insurance coverage. It will apply particularly to people with relapsing multiple sclerosis (RMS) and relapsing-remitting MS (RRMS); with moderate to severe eczema (atopic dermatitis); and those with some cases of severe asthma.
The MoU was signed at the Mohap headquarters by Dr Amin Hussein Al Amiri, assistant undersecretary of the ministry’s public health policy and licensing; Jean-Paul Scheuer, country chair and general manager, Sanofi; and Anas Nofal Al-Safarini, executive director for Middle East and North Africa, Axios Health Education Services.
“Currently, there are a number of multiple sclerosis, atopic dermatitis, and severe asthma patients in the UAE who face cost as a barrier to completing or adhering to their treatment,” said Scheuer.
“We are delighted to be a partner for Ea’nah, which aims to support medically and financially eligible patients to be able to have access to the treatment they need.”
HOW EA’NAH WORKS
>Applies to patients with relapsing multiple sclerosis (RMS) and relapsing-remitting MS (RRMS); with moderate to severe eczema (atopic dermatitis); and those with some cases of severe asthma
>Patient’s Ea’nah journey starts after being diagnosed by a licensed specialist and after a treatment has been prescribed
>If the patient can’t afford the treatment, the physician can refer him to the programme that will be executed by Axios
>He/she will be treated with full transparency and his personal data will remain confidential
>Axios will facilitate the communication among the parties involved, including charity organisations, as well as Mohap and Sanofi
Click here to read more news from @khaleejtimes